Premium
Metabolism, Inflammation, and Tumor Progression
Author(s) -
Simon M. Celeste
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.250.2
Subject(s) - tumor microenvironment , anabolism , tumor progression , cellular adaptation , biology , microbiology and biotechnology , cancer cell , pi3k/akt/mtor pathway , cell growth , metabolic adaptation , cancer , cancer research , metabolism , signal transduction , biochemistry , tumor cells , genetics , gene
Altered tumor cell metabolism is now firmly established as a hallmark of human cancer. Downstream of oncogenic events, metabolism is re‐wired to support cellular energetics and supply the building blocks for biomass. Rapid, uncontrolled proliferation results in tumor growth beyond the reach of existing vasculature and triggers cellular adaptations to overcome limiting nutrient and oxygen delivery. However, oncogenic activation and metabolic re‐programming also elicit cell intrinsic stresses, independent of the tumor microenvironment. To ensure metabolic robustness and stress resistance, pro‐growth signals downstream of oncogene activation or tumor suppressor loss simultaneously activate homeostatic processes. Here, I will summarize adaptive mechanisms co‐opted by common oncogenes, including mTOR, MYC , and RAS . Recurrent themes include: (1) coordination of oncogene‐induced changes in protein and lipid metabolism to sustain endoplasmic reticulum homeostasis, (2) maintenance of mitochondrial functional capacity to support anabolic metabolism, (3) adaptations to sustain intracellular metabolite concentrations required for growth, and (4) prevention of oxidative stress. Ultimately, an understanding of the adaptations required by both tumor cells and recruited inflammatory cells could reveal targetable metabolic vulnerabilities. Support or Funding Information R35 CA197602 (Outstanding Investigator Award)Title: “Metabolic Tumor Suppressors in Renal Cancer: Unprecedented Roles in Disease Progression”3 P01 CA 104838Title: “Cancer Cell Adaptation to Metabolic Stress” This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .